Lipid II

Lipid II
Identifiers
ChEBI CHEBI:27692
ChemSpider 26333143 YesY
Jmol interactive 3D Image
PubChem 46173749
Properties
C94H156N8O26P2
Molar mass 1876.23 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
Infobox references


Lipid II is an amphipathic peptidoglycan precursor molecule involved in the synthesis of the cell wall of bacteria. The molecule is named for its bactoprenol hydrocarbon chain that acts as a lipid anchor, embedding itself in the bacterial cell membrane. The translocation of lipid II across the cell membrane is needed to incorporate its disaccharide-pentapeptide "building block" into peptidoglycan, making Lipid II the target of several antibiotics.

Synthesis

In peptidoglycan biosynthetic pathway

Lipid II is the final intermediate in peptidoglycan biosynthesis. It is formed when the transferase MurG catalyzes addition of N-acetylglucosamine (GlcNAc) to Lipid I, resulting in a complete disaccharide-pentapeptide monomer with a bactoprenol-pyrophosphate anchor. This occurs on the interior of the cytoplasmic membrane, where the bactoprenol chain is embedded in the inner leaflet of the bilayer. Lipid II is then flipped across the membrane to expose the disaccharide-pentapeptide monomer, which is the pentapeptide stem consisting of L-Ala-γ-D-Glu-m-DAP-D-Ala-D-Ala between GlcNAc and N-acetylmuramic acid (MurNAc), for polymerization and cross-linking into peptidoglycan. The remaining bactoprenol-pyrophosphate is then recycled to the interior of the membrane. Lipid II has been referred to as the “shuttle carrier” of peptidoglycan “building blocks”. [1] The essential flippase that translocates lipid II across the cytoplasmic membrane was only published in July 2014, after decades of searching.[2]

Artificial production

A method for artificial production of lipid II has been described. For synthesis of lipid II from UDP-MurNAc pentapeptide and undecaprenol, the enzymes MraY, MurG, and undecaprenol kinase can be used.[3]

Functions

Polymers of lipid II form a linear glycan chain. This reaction is catalyzed by the glycosyltransferases of family 51 (GT51). Transpeptidases cross link the chains and form a net-like peptidoglycan macromolecule. The resulting glycopeptide is essential part of the envelope of many bacteria. Lipid II was estimated to exist at a concentration of less than 2000 molecules per bacterial cell.[4]

Lipid II biosynthesis is functional and essential even in cell wall less organisms like Chlamydia and Wolbachia. It has been hypothesized that maintaining lipid II biosynthesis reflects its role in prokaryotic cell division.[5]

Antibiotics

Since Lipid II must be flipped outside the cytoplasmic membrane before incorporation of its disaccharide-peptide unit into peptidoglycan, it is a relatively accessible target for antibiotics. These antibiotics fight bacteria by either directly inhibiting the peptidoglycan synthesis, or by binding to lipid II to form destructive pores in the cytoplasmic membrane.[6] Examples of antibiotics that target Lipid II include:

Binding

The D-Ala-D-Ala terminus is used by glycopeptide antibiotic vancomycin to inhibit lipid I- and lipid II-consuming peptidoglycan synthesis; in vancomycin-resistant strains vancomycin cannot bind, because a crucial hydrogen bond is lost. Oritavancin also uses the D-Ala-D-Ala terminus, but in addition it uses the crossbridge and D-iso-glutamine in position 2 of the lipid II stem peptide, as present in a number of Gram-positive pathogens, like staphylococci and enterococci. The increased binding of oritavancin through amidation of lipid II can compensate for the loss of a crucial hydrogen bond in vancomycin-resistant strains, [9]

Lantibiotics recognize lipid-II by its pyrophosphate.[1]

Lipid II interacts with human alpha defensins, a class of antimicrobial peptides, such as Defensin, alpha 1. The latter has been used to describe and predict binding of synthetic low-molecular weight compounds created as possible therapeutic agents in treating of Gram-positive infections.[10]

Penicillin-binding protein 4 exchanges d-amino acids into Lipid II (and Lipid I), acting as a transpeptidase in vitro.[11]

References

  1. 1 2 Anton Chugunov,a, Darya Pyrkova, Dmitry Nolde, Anton Polyansky, Vladimir Pentkovsky, Roman Efremov (Apr 16, 2013). "Lipid-II forms potential “landing terrain” for lantibiotics in simulated bacterial membrane". Sci Rep. 3: 1678. doi:10.1038/srep01678. PMC 3627190. PMID 23588060.
  2. ↑ Lok-To Sham, Emily K. Butler, Matthew D. Lebar; et al. (11 July 2014). "MurJ is the flippase of lipid-linked precursors for peptidoglycan biogenesis". Science 345 (6193): 220–222. doi:10.1126/science.1254522.
  3. ↑ Huang LY, Huang SH, Chang YC, Cheng WC, Cheng TJ, Wong CH. (28 July 2014). "Enzymatic synthesis of lipid II and analogues.". Angew Chem Int Ed Engl. 53 (31): 8060–5. doi:10.1002/anie.201402313.
  4. ↑ Y. van Heijenoort, M. Gomez, M. Derrien, J. Ayala, J. van Heijenoort, (1992). "Membrane intermediates in the peptidoglycan metabolism of Escherichia coli: possible roles of PBP 1b and PBP 3.". J. Bacteriol. 174: 3549–3557;.
  5. ↑ Henrichfreise B, Schiefer A, Schneider T; et al. (September 2009). "Functional conservation of the lipid II biosynthesis pathway in the cell wall-less bacteria Chlamydia and Wolbachia: why is lipid II needed?". Mol Microbiol 73 (5): 913–23. doi:10.1111/j.1365-2958.2009.06815.x.
  6. 1 2 3 Heijenoort J (December 2007). "Lipid Intermediates in the Biosynthesis of Bacterial Peptidoglycan". Microbiol Mol Biol Rev 71: 620–635. doi:10.1128/MMBR.00016-07. Retrieved 13 January 2015.
  7. ↑ de Kruijff B, van Dam V, Breukink E (12 November 2008). "Lipid II: A central component in bacterial cell wall synthesis and a target for antibiotics". Prostaglandins Leukot Essent Fatty Acids 79: 117–21. doi:10.1016/j.plefa.2008.09.020. PMID 19008088.
  8. ↑ Wright, Gerard (7 January 2015). "Antibiotics: An irresistible newcomer". Nature 517: 442–444. doi:10.1038/nature14193.
  9. ↑ Münch D, Engels I, Müller A, Reder-Christ K, Falkenstein-Paul H, Bierbaum G, Grein F, Bendas G, Sahl HG, Schneider T (17 November 2014). "Structural variations of the cell wall precursor lipid II - Influence on binding and activity of the lipoglycopeptide antibiotic oritavancin". Antimicrob Agents Chemotherapy 59: 772–781. doi:10.1128/AAC.02663-14. Retrieved 10 January 2015.
  10. ↑ Varney KM1, Bonvin AM, Pazgier M; et al. (2013). "Turning defense into offense: defensin mimetics as novel antibiotics targeting lipid II.". PLoS Pathog 9 (11): e1003732. doi:10.1371/journal.ppat. PMC 3820767. PMID 24244161. Retrieved 10 January 2015.
  11. ↑ Qiao Y, Lebar MD, Schirner K, Schaefer K, Tsukamoto H, Kahne D, Walker S. (22 October 2014). "Detection of lipid-linked peptidoglycan precursors by exploiting an unexpected transpeptidase reaction.". J Am Chem Soc. 136 (42): 14678–81. doi:10.1021/ja508147s.
This article is issued from Wikipedia - version of the Friday, February 12, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.